Möchten Sie immer auf dem neuesten Stand bleiben?

EnGeneIC Honored with 2026 Breakthrough in glioblastoma Biotech Award at Northwell Foundation Lenox Hill Neurosurgery Brain Cancer Gala in New York

Belleville, Illinois, June 04, 2026 (GLOBE NEWSWIRE) -- Allsup, a leading provider of Social Security Disability Insurance (SSDI) representation, return to work and veterans disability appeals...

Oncovita presents promising preclinical data on MVdeltaC, a novel onco-immunotherapy at EACR, 8-11 June 2026, in Budapest

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands...

Ona Therapeutics closes oversubscribed $86.6M Series B financing to advance first-in-class ADCs into clinical development for treatment-resistant cancers

Yet one of oncology's greatest challenges, Glioblastoma, remains largely unsolved.

Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds

AUSTIN, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure,...

Oncolytics Biotech announced the appointment of Steve Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer.

First-in-class oral ERAP1 inhibitor shows 13–36% ORR across 6 solid tumor types in anti-PD-1 resistant patients